Header Logo

Connection

RIMA M SALIBA to Multiple Myeloma

Back to Details
This is a "connection" page, showing publications RIMA M SALIBA has written about Multiple Myeloma.
RIMA M SALIBA
Connection Strength
1.230
Multiple Myeloma
  1. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41.
    View in: PubMed
    Score: 0.095
  2. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
    View in: PubMed
    Score: 0.081
  3. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma. 2020 12; 61(13):3101-3111.
    View in: PubMed
    Score: 0.079
  4. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083.
    View in: PubMed
    Score: 0.075
  5. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.
    View in: PubMed
    Score: 0.071
  6. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535.
    View in: PubMed
    Score: 0.065
  7. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.062
  8. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Apr; 23(4):581-587.
    View in: PubMed
    Score: 0.062
  9. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.
    View in: PubMed
    Score: 0.060
  10. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. 2016 07; 51(7):999-1001.
    View in: PubMed
    Score: 0.058
  11. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.
    View in: PubMed
    Score: 0.057
  12. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.
    View in: PubMed
    Score: 0.048
  13. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.
    View in: PubMed
    Score: 0.044
  14. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011 Apr; 46(4):510-5.
    View in: PubMed
    Score: 0.039
  15. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1122-9.
    View in: PubMed
    Score: 0.038
  16. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7):812-6.
    View in: PubMed
    Score: 0.037
  17. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
    View in: PubMed
    Score: 0.036
  18. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7.
    View in: PubMed
    Score: 0.035
  19. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer. 2008 Apr 01; 112(7):1617-24.
    View in: PubMed
    Score: 0.034
  20. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72.
    View in: PubMed
    Score: 0.032
  21. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007 May; 13(5):543-9.
    View in: PubMed
    Score: 0.031
  22. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar; 39(5):279-83.
    View in: PubMed
    Score: 0.031
  23. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma. 2006 Jul; 47(7):1360-4.
    View in: PubMed
    Score: 0.030
  24. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006 Mar 01; 106(5):1084-9.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.